Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 231 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Irritable Bowel Syndrome (IBS) Clear all
Completed Phase 3 Interventional Results available

Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)

NCT00724126
View directory record Official record
Conditions
Non-Constipation Irritable Bowel Syndrome
Interventions
Rifaximin, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
88
States / cities
Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 83 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2019 · Synced Jul 21, 2026, 11:11 AM EDT
Completed Phase 2 Interventional

Efficacy, Safety and Tolerability of DNK333 (25 mg Bid) in Women With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)

NCT00394173
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea (IBS-D)
Interventions
DNK333, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
180 participants
Timeline
2006 – 2007
U.S. locations
37
States / cities
Tucson, Arizona • North Little Rock, Arkansas • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2017 · Synced Jul 21, 2026, 11:11 AM EDT
Terminated Phase 2 Interventional

Study of the Research Medicine CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D).

NCT06153420
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
CIN-103, Placebo
Drug
Lead sponsor
CinPhloro Pharma, LLC
Industry
Eligibility
18 Years and older
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
53
States / cities
Dothan, Alabama • Huntsville, Alabama • Phoenix, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Jul 21, 2026, 11:11 AM EDT
Terminated Phase 2 Interventional

Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

NCT01887002
View directory record Official record
Conditions
Irritable Bowel Syndrome (IBS)
Interventions
ONO-2952, Placebo comparator
Drug
Lead sponsor
Ono Pharma USA Inc
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
4
States / cities
Boston, Massachusetts • St Louis, Missouri • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2016 · Synced Jul 21, 2026, 11:11 AM EDT
Enrolling by invitation No phase listed Observational

Enabling Microbiomics- Driven Personalized Nutrition

NCT06657001
View directory record Official record
Conditions
Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome (IBS), Celiac Disease, Diarrhea, Constipation, Microbiome, Crohn's Disease, UC - Ulcerative Colitis, Microscopic Colitis, Functional Dyspepsia
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
4,001 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 21, 2026, 11:11 AM EDT
Completed Phase 2 Interventional Results available

Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

NCT00460811
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation
Interventions
Linaclotide Acetate, Matching placebo
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
79
States / cities
Huntsville, Alabama • Chandler, Arizona • Tuscon, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2013 · Synced Jul 21, 2026, 11:11 AM EDT
Completed Not applicable Interventional

A Study of Hemp Hull WFI for IBS Diarrhea

NCT06028035
View directory record Official record
Conditions
Irritable Bowel Syndrome-bile Acid Diarrhea
Interventions
BB01
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Jul 21, 2026, 11:11 AM EDT
Completed Phase 3 Interventional Results available

Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C)

NCT02493452
View directory record Official record
Conditions
Irritable Bowel Syndrome Characterized by Constipation
Interventions
Plecanatide, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
191
States / cities
Birmingham, Alabama • Guntersville, Alabama • Huntsville, Alabama + 157 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Jul 21, 2026, 11:11 AM EDT
Recruiting Phase 2 Interventional

A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)

NCT07519395
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Placebo, Camlipixant
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
108
States / cities
Anniston, Alabama • Guntersville, Alabama • Mobile, Alabama + 88 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 21, 2026, 11:11 AM EDT
Completed Phase 2 Interventional

Diarrhea Predominant Irritable Bowel Syndrome in Females

NCT00461526
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
crofelemer
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
43
States / cities
Huntsville, Alabama • Chandler, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Jul 21, 2026, 11:11 AM EDT
Completed Phase 2 Interventional

Phase 2 Study of MD-1100 Acetate on Gastrointestinal Transit in Patients With C-IBS

NCT00258193
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
MD-1100 Acetate
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 19, 2006 · Synced Jul 21, 2026, 11:11 AM EDT
Not yet recruiting Not applicable Interventional

A Well-Being Intervention for People With IBS

NCT07600047
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Well-Being Intervention
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 21, 2026, 11:11 AM EDT
Completed No phase listed Observational

Efficacy of Psychological Therapies in Patients With Functional Bowel Disorders

NCT04060121
View directory record Official record
Conditions
IBS - Irritable Bowel Syndrome, Constipation
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 28, 2024 · Synced Jul 21, 2026, 11:11 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Activity Changes in Irritable Bowel Syndrome (IBS), Anxiety, and Depression Following the Use of Viome Precision Nutrition Program (VPNP)

NCT04905524
View directory record Official record
Conditions
Depression, Anxiety, IBS - Irritable Bowel Syndrome
Interventions
VIOME Precision Nutrition Program
Dietary Supplement
Lead sponsor
Viome
Industry
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Bothell, Washington
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Jul 21, 2026, 11:11 AM EDT
Terminated Not applicable Interventional Results available

Zemedy Application for Irritable Bowel Syndrome

NCT04723056
View directory record Official record
Conditions
IBS - Irritable Bowel Syndrome
Interventions
Use of Zemedy Application
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated May 27, 2025 · Synced Jul 21, 2026, 11:11 AM EDT
Completed Not applicable Interventional

Neuroimaging and Biomarkers in Chronic Visceral Pain

NCT01602575
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Mindfulness based Stress Reduction Training (MBSR)
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 50 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 13, 2018 · Synced Jul 21, 2026, 11:11 AM EDT
Completed Phase 2 Interventional Results available

Randomized Placebo Controlled Efficacy And Safety Study Investigating GW876008 In Patients With Irritable Bowel Syndrome

NCT00421707
View directory record Official record
Conditions
Irritable Bowel Syndrome (IBS)
Interventions
GW876008, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
17
States / cities
Sherwood, Arkansas • Concord, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2018 · Synced Jul 21, 2026, 11:11 AM EDT
Completed Not applicable Interventional Results available

Self Administered Cognitive Behavior Therapy for Irritable Bowel Syndrome

NCT00738920
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Self Administered Cognitive Behavior Therapy, Therapist Administered Cognitive Behavior Therapy, Behavioral Education and Supportive Therapy
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 70 Years
Enrollment
436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
2
States / cities
Chicago, Illinois • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Jul 21, 2026, 11:11 AM EDT
Completed Not applicable Interventional

Implementing a Low FODMAP Diet in Irritable Bowel Syndrome Patients

NCT03948854
View directory record Official record
Conditions
IBS - Irritable Bowel Syndrome
Interventions
Registered dietitian, On-line video program, Printed handout, Dietitian-led group
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Jul 21, 2026, 11:11 AM EDT
Completed Phase 2 Interventional

A Phase 2 Pilot Study to Assess ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

NCT01896583
View directory record Official record
Conditions
Diarrhea Predominant Irritable Bowel Syndrome
Interventions
ASP7147, Placebo
Drug
Lead sponsor
Seldar Pharma, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
13
States / cities
Phoenix, Arizona • Encino, California • La Mesa, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Jul 21, 2026, 11:11 AM EDT
Completed Not applicable Interventional

Investigation of Linaclotide's Effect on the Bi-directional Brain and Gut Axis in IBS-C Patients

NCT02078323
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation (IBS-C)
Interventions
Linaclotide, Placebo
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 64 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 22, 2018 · Synced Jul 21, 2026, 11:11 AM EDT
Completed Phase 2 Interventional

Eight-Weeks Of Treatment With Talnetant In Subjects With Irritable Bowel Syndrome (IBS)

NCT00101985
View directory record Official record
Conditions
Irritable Colon
Interventions
talnetant
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
741 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
70
States / cities
Chandler, Arizona • Phoenix, Arizona • North Little Rock, Arkansas + 63 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2015 · Synced Jul 21, 2026, 11:11 AM EDT
Completed Not applicable Interventional

Irritable Bowel Syndrome and Food Sensitivity

NCT02186743
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Personalized Dietary Advice
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 17, 2017 · Synced Jul 21, 2026, 11:11 AM EDT
Completed Phase 3 Interventional Results available

Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C

NCT04166058
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation, Functional Constipation
Interventions
Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers), Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 18 Years
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
65
States / cities
Birmingham, Alabama • Foley, Alabama • Saraland, Alabama + 50 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Jul 21, 2026, 11:11 AM EDT